1. $1.3 Billion from NIH SBIR/STTR
The National Institutes of Health (NIH) invites small businesses to apply for the upcoming deadlines of the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs, with submissions due on January 5 and April 5, 2025. These programs offer critical funding to support innovative health-related research and development.
Phase I grants, aimed at early-stage, proof-of-concept projects, award up to $314,363 over 6-12 months. Successful Phase I projects may advance to Phase II, where they can receive up to $2.09 million for further development over two years. These awards provide essential support to small businesses developing solutions to address key health challenges, enabling the commercialization of breakthroughs that can benefit public health nationwide.
Read more here →
2. $600K from the NCI
The National Cancer Institute (NCI) has announced the Cancer Prevention and Control Clinical Trials Planning Grant Program (PAR-25-104), aimed at supporting the development of well-planned clinical trials across the cancer prevention and control spectrum. This initiative focuses on areas such as prevention, interception, cancer-related health behaviors, screening, early detection, healthcare delivery, management of treatment-related symptoms, supportive care, and improving long-term outcomes for cancer survivors.
The R34 Planning Grant provides up to $450,000 in direct costs over a maximum project period of three years, with no more than $225,000 allocated in any single year. This funding is intended to help researchers address critical information gaps, refine study designs, and enhance the feasibility and rigor of future clinical trials. By facilitating thorough preparatory studies, the program aims to reduce protocol changes, minimize expenses, and ensure the successful completion of subsequent trials.
Read more here →
Featured Winner
MelliCell Inc. awarded $275K from NIH
MelliCell Inc., headquartered in Newton, Massachusetts, is a pioneering biotechnology company specializing in adipocyte-based therapies for chronic diseases. In October 2024, MelliCell was awarded a prestigious Small Business Innovation Research (SBIR) grant from the National Institutes of Health’s National Institute of Diabetes and Digestive and Kidney Diseases (NIH/NIDDK). This funding supports their collaboration with Mass General Brigham to advance innovative treatments targeting diabetes and obesity. MelliCell’s core technology enables the generation of mature human fat tissue at scale, unlocking potential for novel biologic drugs and therapeutic interventions. This grant underscores MelliCell’s commitment to addressing chronic diseases through cutting-edge adipocyte therapies
Read more here →